Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

计划入组 171 人 · 首次发布于 2024 年 8 月 22 日

ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

计划入组 20 人 · 首次发布于 2015 年 9 月 16 日

A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors

计划入组 31 人 · 首次发布于 2009 年 10 月 30 日

STX-241

MTX-241

PDL-241

Onyx Pharmaceuticals, Inc.

United States

BURAPHA UNIVERSITY

Thailand

Scarless Laboratories, Inc.

United States

Pierre Fabre and Scorpion Therapeutics Initiate Phase I/II Trial of EGFR Inhibitor PFL-241/STX-241 in NSCLC

Pierre Fabre Acquires Global Rights to Next-Generation EGFR Inhibitors for NSCLC Treatment

Eli Lilly Acquires Scorpion's Cancer Drug STX-478 in $2.5 Billion Deal